leisure time -WSS

leisure time

author：comprehensive 2025-10-01 18:44:44 - browse：176

Humana’s Medicare Advantage enrollees got care in the hospital and physician clinics way more often than the company predicted at the end of 2023, forcing the health insurance giant on Thursday to drastically slash its profit projections for both 2023 and 2024.

Those higher medical costs will wipe away more than $775 million of profit that Humana had expected to bank for 2023. Humana also is “currently assessing the expected impact of emerging utilization trends on its 2024 outlook, which is anticipated to be material if current trends continue,” according to the company’s update to investors.

Humana’s bad news for Wall Street didn’t end there: The company said it appears it only added just 100,000 new Medicare Advantage members from the most recent enrollment period that ended last month — down from estimates that it would enroll anywhere from 325,000 to 435,000 people.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

hotspot

WSS

US recommends Americans reconsider traveling to China due to arbitrary law enforcement, exit bans

EPA limits use of carcinogenic gas for sterilizing medical devices

Medicare coverage of Wegovy, once blocked, now looks possible

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

4 dead, 2 in stable condition in Philadelphia shooting: Police

First U.S. drug developed to treat liver disease MASH is approved

hotspot

leisure time

leisure time

Sports medicine is finally prioritizing gender equality

July 4th fireworks can be stressful for dogs. These 6 tips can keep them calm and safe

State Dept. review finds Biden bears some blame for Afghanistan failures

How many hemophilia patients actually want gene therapy?

Virginia high school admissions case could be legal follow

Why depression after traumatic brain injury is distinct

Hepatitis C has a cure — but many Americans still lack access to it

How to save health care price transparency rules

BioMarin wins approval for gene therapy to treat hemophilia A

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

hotspot

The Democratic Party promised to overhaul its primaries. Doing that has been anything but simple

WuXi out of biotech trade group, U.S. and China relations to blame

John Green on his newest strategy for fighting tuberculosis

Kremlin open to talks over potential prisoner swap involving detained US reporter Evan Gershkovich

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

entertainment

hotspot

focus

entertainment